Valentijn Schweitzer

Medical doctor | Epidemiologist | Resident Clinical Microbiology @UMCUtrecht | Member of @TAESCMID

[ESCMID @ESCMID]

The AMR Action Subcommittee and Study Group for Artificial intelligence and Digitalisation (ESGAID) recently published a perspective on the implications of using AI in the fight against #AMR. Check it out: https://t.co/xkSAFpVR1D

[ESCMID @ESCMID]

Check out this article by two of our AMR Action Subcommittee members exploring the importance of building connections between science and policy as we address the global concern of #AMR.

https://t.co/hwqJTVK5NL
#WAAW2024 #escmidAMR #AntimicrobialResistance

[Valentijn Schweitzer @schweitzer_va]

@BradSpellberg The infectious mimickers will likely bias to non-inferiority and not inferiority right?

[Marc Bonten @MarcBonten]

Annual meeting of the PRImAVeRA consortium that investigates potential effects of vaccines & monoclonal antibodies on infections caused by antibiotic resistant bacteria. @IHIEurope

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🔥 Topic in Infectious Diseases!
High-quality clinical data are needed!
🆕️⚡️⚡️Favourable effect of clavulanic acid on the minimum inhibitory concentrations of cefixime and ceftibuten in ESBL-producing Escherichia coli and Klebsiella pneumoniae #idxposts
https://t.co/6abgRFVBTe

[Ferry Hagen 🔬🧫🧬 @ferryhagen]

Improving disseminated histoplasmosis diagnosis in HIV/AIDS patients in Suriname: The role of a urine lateral flow assay #AZP @IenI_UMCUtrecht @diakhuis @amsterdamumc @_Westerdijk_ @InFocusLatAm @ISHAM_Mycology
@eurconfmedmycol @efisg_escmid
https://t.co/1FeZpNUcra

[Robert Dickson @robertpdickson]

Most patients with sepsis don't need anti-anaerobic antibiotics. But most get them anyway. Why not, what's the harm?

I worry the harm is considerable.

Our new study in @JAMAInternalMed: using a 15-month pip-tazo shortage to answer this question.

1/n

https://t.co/1nOhsUaio0

[Valentijn Schweitzer @schweitzer_va]

@HeimanW @NVMM_NL Dit zei ik ook tegen onze longartsen maar de reactie was: welke evidence is er nu bijgekomen om te stoppen met anaerobe dekking? Deimplementatie van dogma's blijkt ook lastig

[Valentijn Schweitzer @schweitzer_va]

@HeimanW @NVMM_NL Of tijd voor een goede RCT? Ik vraag me af of observationele data voldoende is om dit boek voor goed te kunnen sluiten.

[David Paterson @davidantibiotic]

Do clinical trials of antimicrobial agents give clinicians the information they need in order to change guidelines and revise their prescribing patterns?
A thread on a new way to analyze clinical trial results

[David Paterson @davidantibiotic]

Congratulations @InfectiousMoYin @ADVANCE__ID on a great VAP trial! https://t.co/7thpG6PdtM

[Valentijn Schweitzer @schweitzer_va]

@sarah_delliere @a_alanio Interesting study Sarah! We usually worry about lower specificity for aspiration compared to BAL, not the sensitivity. Do you agree?

[Anna @Annadulafungin]

🍄 Great to see that fungi are getting more recognition -we certainly are seeing them more and more in medical practice . I am very honoured to be here -excited to discuss with Dutch colleagues on their clinical experience and practice. @ferryhagen @_Westerdijk_ @schweitzer_va

[Valentijn Schweitzer @schweitzer_va]

@Annadulafungin @ESCMID @_Westerdijk_ @ferryhagen Nice, have fun! Does this include a visit to our hospital? 😁

[Axel Hamprecht @a_hamprecht]

Have you seen a carbapenemase-producing Proteus (CPP) isolate in your microbiology lab? Probably yes, but likely without noticing. A thread on our latest publication @CMIJournal
@UniOldenburg
#IDtwitter #microrounds
https://t.co/xylu1nBq5m
1/x

[Valentijn Schweitzer @schweitzer_va]

@EdHutchison @PharmDFarmD @drtimothyli I reraise with penicillin (if on iv treatment), otherwise amoxicillin! :)

[Luke Turner 🦠 @MicroLukas]

Wondering how beta-lactam resistance occurs in Staphylococcus aureus (e.g. MRSA)?

A short 🧵 on the two most common mechanisms of beta-lactam resistance in S. aureus ...

[Sarah Dellière is on Bluesky 🦋 @sarah_delliere]

ß-D-glucans in CSF for non-crypto 🍄 infection.
Sensitivity 72% in proven/probable IFIs. Specificity 82% in well defined control population ⚠️false positive w/ bacterial infections, strokes, drug toxicity ⬇️ @Jeanne_big

https://t.co/9A58ljONuh

[Valentijn Schweitzer @schweitzer_va]

@ABsteward @OFIDJournal @DrAndreKalil If I understand correctly they modeled disease progression under treatment which is different than correcting for baseline imbalances.

[Valentijn Schweitzer @schweitzer_va]

@ABsteward @OFIDJournal @DrAndreKalil Post-hoc adjustment of observed baseline imbalances in RCTs is not needed and inappropriate.
See https://t.co/cV5PRfoB4T and Seven myths of randomisation in clinical trials by Stephen Senn.